ELTX (Elicio Therapeutics) Other Operating Expense: $-0.41 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELTX Elicio Therapeutics Inc ELTX
28 GF Score
Price $3.00
! 1 Warning Sign
View Full Analysis

What is Elicio Therapeutics Other Operating Expense?

Elicio Therapeutics ELTX -4.76% 28 Other Operating Expense is $-0.41 Mil as of Mar. 2026. GuruFocus rates ELTX with a GF Score™ of 28/100. The stock has 1 warning sign investors should review.

Elicio Therapeutics's Other Operating Expense for the three months ended in Mar. 2026 was $0.00 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-0.41 Mil.

Elicio Therapeutics's quarterly Other Operating Expense stayed the same from Sep. 2025 ($0.00 Mil) to Dec. 2025 ($0.00 Mil) and stayed the same from Dec. 2025 ($0.00 Mil) to Mar. 2026 ($0.00 Mil).

Elicio Therapeutics's annual Other Operating Expense increased from Dec. 2023 ($-0.00 Mil) to Dec. 2024 ($-0.00 Mil) but then declined from Dec. 2024 ($-0.00 Mil) to Dec. 2025 ($-0.41 Mil).

Elicio Therapeutics Other Operating Expense Historical Data

* Premium members only.

The historical data trend for Elicio Therapeutics's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Elicio Therapeutics Other Operating Expense Chart

Elicio Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Operating Expense
Get a 7-Day Free Trial 0.00 -0.00 -0.00 -0.00 -0.41

Elicio Therapeutics Quarterly Data
Mar20 Dec20 Mar21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -0.42 0.00 0.00 0.00
ELTX
28GF Score
Elicio Therapeutics Inc ELTX
Other Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Elicio Therapeutics Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.41 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Other Operating Expense of $-0.41 Mil mean?
Elicio Therapeutics (ELTX) has a Other Operating Expense of $-0.41 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Elicio Therapeutics and its competitors.
Is Elicio Therapeutics' Other Operating Expense too high?
Elicio Therapeutics' current Other Operating Expense is $-0.41 Mil. Overall, Elicio Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Elicio Therapeutics' Other Operating Expense compare to GOSS and GANX?
Elicio Therapeutics' Other Operating Expense of $-0.41 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Biotechnology company?
A good Other Operating Expense depends on the Biotechnology industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Elicio Therapeutics and its competitors. Elicio Therapeutics's current Other Operating Expense is $-0.41 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elicio Therapeutics stock overvalued right now?
Elicio Therapeutics (ELTX) has a current Other Operating Expense of $-0.41 Mil. The current Other Operating Expense is $-0.41 Mil. Elicio Therapeutics' overall GF Score™ is 28/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Elicio Therapeutics (ELTX), the current Other Operating Expense is $-0.41 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Elicio Therapeutics Business Description

Other Exchanges 9HA:Germany
Address 451 D Street, Suite 501, 5th Floor, Boston, MA, USA, 02210
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.
28GF Score

Get the complete analysis for ELTX

Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.00
Price